Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?

[1]  M. Färkkilä,et al.  Outcome After Discontinuation of TNF&agr;-blocking Therapy in Patients with Inflammatory Bowel Disease in Deep Remission , 2014, Inflammatory bowel diseases.

[2]  M. Färkkilä,et al.  Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD. , 2013, Journal of Crohn's & colitis.

[3]  J. Belaiche,et al.  Consecutive Fecal Calprotectin Measurements to Predict Relapse in Patients with Ulcerative Colitis Receiving Infliximab Maintenance Therapy , 2013, Inflammatory bowel diseases.

[4]  Thomas J. Smith,et al.  564 Elevated Faecal Calprotectin Predicts Disease Progression in Crohn's Disease , 2013 .

[5]  M. Färkkilä,et al.  Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease , 2013, Scandinavian journal of gastroenterology.

[6]  A. Morris,et al.  A prospective single‐centre evaluation of the intra‐individual variability of faecal calprotectin in quiescent Crohn's disease , 2013, Alimentary pharmacology & therapeutics.

[7]  M. Färkkilä,et al.  Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNF&agr; blocking agents , 2012, Inflammatory bowel diseases.

[8]  Ren Mao,et al.  Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta‐analysis of prospective studies , 2012, Inflammatory bowel diseases.

[9]  J. Seidelin,et al.  Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study , 2012, Scandinavian journal of gastroenterology.

[10]  M. Vos,et al.  P274 Close monitoring of CRP and fecal calprotectin levels to predict relapse in Crohn's disease patients. A sub-analysis of the STORI study , 2012 .

[11]  M. Regueiro,et al.  Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. , 2012, Inflammatory bowel diseases.

[12]  R. Porcher,et al.  Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. , 2012, Gastroenterology.

[13]  V. de Lédinghen,et al.  Prediction of Crohn’s disease relapse with faecal calprotectin in infliximab responders: a prospective study , 2011, Alimentary pharmacology & therapeutics.

[14]  Clarence K. Wong,et al.  Maintenance of clinical benefit in Crohn’s disease patients after discontinuation of infliximab: long‐term follow‐up of a single centre cohort , 2010, Alimentary pharmacology & therapeutics.

[15]  J. Gisbert,et al.  Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? , 2010, Journal of Crohn's & colitis.

[16]  I. Ayadi,et al.  Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study , 2010, European journal of gastroenterology & hepatology.

[17]  J. Mate,et al.  Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse , 2009, Inflammatory bowel diseases.

[18]  M. Färkkilä,et al.  Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings , 2008, Alimentary pharmacology & therapeutics.

[19]  R. D'Incà,et al.  Can Calprotectin Predict Relapse Risk in Inflammatory Bowel Disease? , 2008, The American Journal of Gastroenterology.

[20]  M. Färkkilä,et al.  Crohn's disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohn's disease activity index and endoscopic findings , 2008, Inflammatory bowel diseases.

[21]  A. Schoepfer,et al.  Discriminating IBD from IBS: Comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies , 2008, Inflammatory bowel diseases.

[22]  A. Darzi,et al.  Diagnostic Precision of Fecal Calprotectin for Inflammatory Bowel Disease and Colorectal Malignancy , 2007, The American Journal of Gastroenterology.

[23]  Philippe Marteau,et al.  A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. , 2007, Gastroenterology.

[24]  W. Best.  Predicting the Crohn's disease activity index from the harvey‐bradshaw index , 2006, Inflammatory bowel diseases.

[25]  M. Bottai,et al.  Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease , 2005, Gut.

[26]  P. Rutgeerts,et al.  Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. , 2004, Gastrointestinal endoscopy.

[27]  A. Røseth,et al.  Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease , 2004, Scandinavian journal of gastroenterology.

[28]  A. Poullis,et al.  Emerging role of calprotectin in gastroenterology , 2003, Journal of gastroenterology and hepatology.

[29]  M. Cappa,et al.  Does Graves’ Disease during Puberty Influence Adult Bone Mineral Density? , 2002, Hormone Research in Paediatrics.

[30]  P. Rutgeerts,et al.  A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. , 2002, Gastroenterology.

[31]  E. Husebye,et al.  Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm , 2001, American Journal of Gastroenterology.

[32]  A. Zinsmeister,et al.  Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy , 2000, American Journal of Gastroenterology.

[33]  B. Thjódleifsson,et al.  A simple method for assessing intestinal inflammation in Crohn's disease , 2000, Gut.

[34]  I. Bjarnason,et al.  Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. , 2000, Gastroenterology.

[35]  A. Røseth,et al.  High prevalence of NSAID enteropathy as shown by a simple faecal test , 1999, Gut.

[36]  A. Røseth,et al.  Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. , 1999, Scandinavian journal of gastroenterology.

[37]  P. Rutgeerts,et al.  Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. , 1998, Gastroenterology.

[38]  J. Jahnsen,et al.  Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. , 1997, Digestion.

[39]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.